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24 What is the key question?
25 Can we generate an in vivo model of SARS-CoV-2 infection based on standard 
26 laboratory mice, for testing new therapeutics such as passive vaccination with anti-
27 SARS-CoV-2 antibodies?
28
29 What is the bottom line?
30 Using a mimic of SARS-CoV-2 based on recombinant lentivirus pseudotyped with 
31 SARS-CoV-2 Spike protein, we created a humanised in vivo mouse model of SARS-
32 CoV-2 infection, and showed long-term, passive vaccination by gene transfer of 
33 antibody sequences.
34
35 Why read on? 
36 Our humanised mouse model and SARS-CoV-2 mimic offers a rapid, inexpensive, and 
37 efficient method to evaluate therapeutic interventions to halt SARS-CoV-2 infection.  
38 It will be of interest to researchers studying COVID-19 and other respiratory pathogens 
39 and, importantly, can be implemented under standard laboratory biosafety conditions 
40 without the need to breed and maintain transgenic animals.  
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41 Abstract (228 words)
42
43 Background
44 The novel coronavirus disease (COVID-19) pandemic continues to be a worldwide 
45 threat and effective antiviral drugs and vaccines are being developed in a joint global 
46 effort. However, some elderly and immune-compromised populations are unable to 
47 raise an effective immune response against traditional vaccines. 
48
49 Aims
50 We hypothesised that passive immunity engineered by the in vivo expression of anti-
51 SARS-CoV-2 monoclonal antibodies (mAbs), an approach termed vectored-
52 immunoprophylaxis (VIP), could offer sustained protection against COVID-19 in all 
53 populations irrespective of their immune status or age.
54
55 Methods
56 We developed three key reagents to evaluate VIP for SARS-CoV-2: (i)  we engineered 
57 standard laboratory mice to express human ACE2 via rAAV9 in vivo gene transfer, to 
58 allow in vivo assessment of SARS-CoV-2 infection, (ii) to simplify in vivo challenge 
59 studies, we generated SARS-CoV-2 Spike protein pseudotyped lentiviral vectors as a 
60 simple mimic of authentic SARS-CoV-2 that could be used under standard laboratory 
61 containment conditions; and (iii) we developed in vivo gene transfer vectors to express 
62 anti-SARS-CoV-2 mAbs.
63
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64 Conclusions
65 A single intranasal dose of rAAV9 or rSIV.F/HN vectors expressing anti-SARS-CoV-
66 2 mAbs significantly reduced SARS-CoV-2 mimic infection in the lower respiratory 
67 tract of hACE2-expressing mice. If translated, the VIP approach could potentially offer 
68 a highly effective, long-term protection against COVID-19 for highly vulnerable 
69 populations; especially immune-deficient/senescent individuals, who fail to respond to 
70 conventional SARS-CoV-2 vaccines. The in vivo expression of multiple anti-SARS-
71 CoV-2 mAbs could enhance protection and prevent rapid mutational escape.
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72 Introduction 
73 The current Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute 
74 Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has ravaged the globe. Many of 
75 the vaccine candidates being developed have yielded positive results in clinical trials, 
76 generating high levels of antibodies 1 2, and providing clinical protection 3. However, 
77 the induction of such protective immunity is entirely dependent on the treated 
78 individual’s immune system to develop antigen-specific immunity, and it remains 
79 unclear whether diverse populations will respond to the antigen-based vaccine regimens 
80 to the same extent. In all likelihood, people will respond to the current vaccines to 
81 different degrees and some groups of individuals with poor immunogenicity will 
82 struggle to raise a protective immune response. 
83
84 An alternative strategy is to use vector-mediated immunoprophylaxis (VIP) against 
85 SARS-CoV-2 infection, which could circumvent some limitations. VIP involves the 
86 delivery of genes encoding neutralizing antibodies into target cells via gene transfer; 
87 subsequently, the monoclonal antibody (mAb) protein is synthesised in vivo, secreted 
88 into the local milieu and ultimately the systemic circulation. Viral vectors can be 
89 exploited for VIP, including recombinant Adeno-Associated Virus (rAAV) vectors that 
90 provide long-term and stable transgene expression with low vector immunogenicity and 
91 high tolerability 4. In particular, rAAV-mediated delivery of neutralizing antibodies is 
92 a promising strategy against Human Immunodeficiency Virus (HIV) 5, Filovirus 6, 
93 Respiratory syncytial virus (RSV) 7, and Influenza virus (IV) 8-10. More recently, 
94 recombinant Simian Immunodeficiency Virus (SIV) pseudotyped with the Fusion (F) 
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95 and Haemagglutinin-Neuraminidase (HN) surface glycoproteins from Sendai virus 
96 (rSIV.F/HN) 11 has also been used to express broadly neutralizing mAbs in the airways 
97 to protect against a supra-lethal influenza infection 9. To our knowledge, there have 
98 been no published, peer-reviewed reports on the application of VIP for SARS-CoV-2.
99
100 In this study, we delivered the rAAV and rSIV.F/HN gene transfer platforms via 
101 intranasal and intramuscular administration routes to express NC0321, a prototypical 
102 SARS-CoV-2 neutralizing mAb. We then challenged the mAb-treated mice with S-LV 
103 (a SARS-CoV-2 pseudovirus created from a recombinant HIV1 lentiviral vector 
104 pseudotyped with the D614G derivative of the SARS-CoV-2 Spike (S) protein). We 
105 used S-LV infection to investigate the prophylactic efficacy of the NC0321 mAb 
106 produced by the in vivo gene transfer vectors. These proof-of-principle studies 
107 demonstrate that viral infection can be inhibited by vector-mediated delivery of anti-
108 SARS-CoV-2 mAb genes. We call this strategy ‘COVID-19 Vectored 
109 Immunoprophylaxis’ (COVIP). Importantly, the COVIP approach could offer potent 
110 protection against authentic SARS-CoV-2 infection in populations that fail to respond 
111 to conventional SARS-CoV-2 vaccines.
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112 Materials and Methods
113 Detailed methods can be found in the online supplementary information.
114
115 Results 
116 S-LV as a mimic of SARS-CoV-2 
117 We aimed to generate a non-replicative mimic of SARS-CoV-2 capable of a single-
118 cycle of infection for use under simple laboratory conditions. Importantly, cellular entry 
119 of SARS-CoV-2 relies on the viral Spike protein binding to the Angiotensin-converting 
120 enzyme 2 (ACE2) receptor, an interaction synergised by cleavage of Spike by 
121 Transmembrane protease Serine 2 (TMPRSS2) 12. We hypothesised that a third-
122 generation HIV lentiviral vector pseudotyped with the SARS-CoV-2 Spike protein 
123 (termed S-LV) would retain similar receptor dependencies. We found that S-LV 
124 particles could be readily prepared and showed that, similar to SARS-CoV-2 and other 
125 SARS-CoV-2 surrogates 12, S-LV infection of cells in vitro was absolutely dependent 
126 on hACE2 and was significantly enhanced in the presence of hTMPRSS2 (Fig 1A). 
127
128 rAAV vector can mediate hACE2 expression in vivo
129 Since S-LV pseudovirus could mimic SARS-CoV-2 infection in vitro, we next aimed 
130 to create an in vivo infection model to evaluate potential therapeutic interventions. 
131 However, laboratory mice are not naturally susceptible to Coronavirus infection due to 
132 ACE2 receptor incompatibility 13. Others have chosen to generate, breed and utilise 
133 hACE2 expressing transgenic mice to overcome this limitation 14. As a more accessible 
134 alternative, we provided human (h)ACE2 and (in some studies) hTMPRSS2 in trans to 































































Confidential: For Review Only
8
135 facilitate SARS-CoV-2 or S-LV entry, thus generating a murine model of SARS-CoV-2 
136 infection.
137
138 We used in vivo delivery of both rAAV9 and rAAV6.2 vectors to provide the necessary 
139 cellular receptors. Vectors carrying hACE2 or the reporter eGFP were administered to 
140 mouse lungs via intranasal instillation (I.N.) and 14 days post-delivery, we observed 
141 abundant eGFP expression with both vectors. For rAAV9, eGFP expression was largely 
142 restricted to the parenchyma of the lung, predominantly in cells with an Alveolar Type 
143 I (ATI) morphology. In contrast, rAAV6.2 directed eGFP expression in both the lung 
144 parenchyma, predominantly in cells with an Alveolar Type II (ATII) morphology, and 
145 in cells of the conducting airway (Fig 1B). The significant sequence homology between 
146 human and murine (m)ACE2 meant that distinguishing their expression by IHC was 
147 challenging 15, therefore in situ hybridization (ISH) was used to detect vector-derived 
148 hACE2 expression via the linked WPRE sequence. Fig 1C shows that consistent with 
149 the observed eGFP signal, hACE2 expressed from rAAV9 was rarely observed in the 
150 conducing airway and was largely restricted to the lung parenchyma, while rAAV6.2 
151 vector expression was observed in cells of the conducting airway, terminal bronchi and 
152 alveoli.
153
154 rAAV vector-mediated hACE2 expression facilitates S-LV infection
155 Having established that hACE2 and hTMPRSS2 could be provided in trans to the 
156 murine airway via rAAV vectors, we then asked whether hACE2 could facilitate S-LV 
157 transduction in murine lungs, and whether infectivity could be enhanced by hTMPRSS2 
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158 co-expression. To address this, mice were first treated I.N. with 7E10 genome copies 
159 (GC) rAAV6.2 hACE2, 1E11 GC rAAV.hACE2, or cocktails of rAAV9.hACE2 and 
160 rAAV9.hTMPRSS2 vectors where the total rAAV9 dose delivered was fixed at 1E11 
161 GC. Mice were infected 14 days later with 890 ng of p24 of S-LV Luciferase (I.N.) and 
162 monitored for S-LV-dependent luciferase expression kinetics (Fig 2A). Consistent with 
163 the in vitro study findings, mouse lungs were refractory to S-LV infection in the absence 
164 of hACE2 expression. In contrast, mouse lungs that were primed with hACE2 by either 
165 rAAV9 or rAAV6.2 showed abundant luciferase expression after infection with S-LV. 
166 Luciferase activity was detectable above background from as early as 24 hours after S-
167 LV infection with signal intensity increasing to a peak at approximately 7 days (Fig 
168 2B). Consistent with the lentiviral vector heritage of S-LV, luciferase expression was 
169 long-lived, though it should be noted that an early peak of signal intensity 
170 (approximately 7 days post-infection) fell to plateau at around 21 days post-infection 
171 (Fig 2C). The S-LV mediated luciferase expression was monitored over a 38-day time-
172 course, showing luciferase signal intensity achieved with hACE2 priming was more 
173 than 200-fold greater than without priming (p<0.0001, Fig 2D). While the signal 
174 intensity achieved with rAAV6.2.hACE2 priming tended to be ~2 fold lower than that 
175 achieved with rAAV9 (approximately 100-fold over no priming) this difference failed 
176 to reach significance (p=0.2722). Nevertheless, the higher absolute signal observed 
177 using rAAV9.hACE2, together with the substantially lower production yields of 
178 rAAV6.2.hACE2, which ultimately restricted the rAAV6.2 hACE2 priming dose that 
179 could be delivered. Interestingly, and in contrast with our in vitro findings, 
180 incorporation of 1E10 GC of rAAV9.hTMPRSS2 had no positive benefit on S-LV 
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181 infection in vivo and the use of 5E10 rAAV9.hTMPRSS2 significantly reduced 
182 (p=0.0221) the S-LV signal to only 60-fold over background (Fig 2D). Together, these 
183 data led us to focus on rAAV9.hACE2 priming in all subsequent studies.
184
185 S-LV kinetics and dose-dependency in hACE2-expressing mice
186 To gain a more thorough insight into the transduction kinetics of S-LV, we performed 
187 dose titration studies in hACE2-expressing mice which were infected with 0, 9.4, 94, 
188 470, and 940 ng p24 of S-LV (Fig 3A). We observed a dose-dependent increase in S-
189 LV mediated luciferase expression (Fig 3B). As in the previous studies, in vivo 
190 bioluminescence in each hACE2-expressing mouse rose to a peak at approximately 7 
191 days post-infection (Fig 3C). Notably, infection with either 470 or 940 ng p24 of S-LV 
192 produced comparable lung luciferase activity (p>0.9999, Fig 3D), consistent with S-
193 LV infection in this model being limited by the rAAV9-mediated hACE2 expression 
194 above 470 ng of p24 of S-LV. Importantly, the 470 ng p24 dose of S-LV produced 
195 significantly higher lung luciferase activity than the 0, 9.4 or 94 ng p24 dose of S-LV 
196 (p<0.001, p<0.001 and p=0.0012 respectively). To avoid any limitation in S-LV signal, 
197 we proceeded with the saturating S-LV challenge dose of 470 ng p24 S-LV in 
198 subsequent therapeutic protection studies.
199
200 In vitro and In vivo IgG expression mediated by AAV and SIV.F/HN vectors 
201 To establish proof-of-principle for COVIP, we wished to express in vivo a potent anti-
202 SARS-CoV-2 mAb to inhibit S-LV infection in our mouse model. The mAb NC0321 
203 was originally isolated from the convalescent serum of a patient recovered from SARS-
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204 CoV-2 infection in China (Zhao JC, in preparation). We established that the single-
205 open reading frame version of NC0321 used (Fig 4A & Supplementary Fig 1A) could 
206 both potently bind the receptor binding domain (RBD) portion of SARS-CoV-2 Spike 
207 protein (Fig 4B) and block S-LV infection in our in vitro cell model (Fig 4C). We then 
208 examined the ability of alternative gene transfer vector configurations to mediate 
209 expression of NC0321 IgG in vivo. Following delivery of rSIV.F/HN.NC0321 and 
210 rAAV9.NC0321 vectors via the I.N. route, and rAAV8.NC0321 via intramuscular 
211 injection (I.M.), we monitored NC0321 expression levels in mouse sera at 7, 14 and 28 
212 days post-delivery. All groups treated with an NC0321 expressing vector contained 
213 significantly more NC0321 mAb in the serum than control animals (p<0.0001; Fig 4D). 
214 Delivery of rAAV8 via the I.M. route resulted in the most rapid accumulation of 
215 NC0321, reaching a peak (~3.9 µg/mL) in serum within 7 days, which was essentially 
216 sustained to the end of the time-course (~2.5 µg/mL at day 28). Vectors delivered via 
217 the I.N. route had both slower kinetics (reaching a plateau after approximately 14 days 
218 post-delivery) and lower, sustained serum levels (~0.8 µg/mL and ~0.3 µg/mL for 
219 rAAV9 and rSIV.F/HN respectively). At the end of the study, 28 days after vector 
220 delivery, all mice were culled and BALF collected to determine levels of NC0321 in 
221 lung epithelial lining fluid (ELF). All groups treated with vector expressing NC0321 
222 contained significantly more NC0321 mAb in the ELF than control animals (all p<0.05; 
223 Fig 4E). Delivery via rAAV9 I.N. treatment resulted in the highest NC0321 ELF levels 
224 (~65 µg/mL), significantly higher than achieved with rSIV.F/HN, also delivered via the 
225 I.N. route (~3 µg/mL; p=0.0055). In contrast, rAAV8 I.M. delivery was associated with 
226 intermediate ELF levels (~18 µg/mL) that were not significantly different (p=0.7451) 
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227 from those achieved with rAAV9. Taken together, these observations indicate that gene 
228 transfer vectors expressing anti-SARS-CoV-2 mAb, delivered via I.N. (rAAV9 or 
229 rSIV.F/HN) or I.M. (for rAAV8) routes, results in abundant serum and ELF 
230 accumulation of mAb protein. 
231
232 In vivo viral vector-mediated protection against S-LV infection  
233 After confirming NC0321 mAb expression in mouse sera via three different in vivo 
234 gene transfer strategies, it was important to determine whether the expressed mAb could 
235 reduce S-LV infection. As a control, we utilised gene transfer vectors expressing anti-
236 influenza mAb T1-3B 16 of the same IgG isotype as NC0321. Twenty-one days after 
237 hACE2 and NC0321/T1-3B expression was established in the lungs of BALB/c mice, 
238 we infected the study animals from Fig 4D/E with 470 ng p24 of S-LV (Fig 5A). 
239 Luciferase expression mediated by S-LV infection was monitored for 7 days post 
240 challenge; in vivo imaging data are presented for representative animals (Fig 5B), and 
241 all individual mice and treatment groups (Supplementary Fig 1B&C). While minor 
242 variations in the S-LV signal between the three T1-3B treatment groups were noted, 
243 most likely a consequence of the complex study design using three gene transfer vectors 
244 (Supplementary Fig 1D), these failed to reach significance suggesting no major impact 
245 on functional mAb or hACE2 levels. Crucially, over the course of the study (Fig 5C), 
246 the S-LV luciferase signal intensity achieved upon treatment with rAAV9.NC0321 was 
247 substantially reduced (~ 0.71 log or 79.6% protection; p=0.004 compared with T1-3B 
248 treatment. Similarly, treatment with rSIV.F/HN NC0321 also significantly reduced the 
249 S-LV luciferase signal intensity (~ 0.25 log or 55.1% protection; p=0.0124). 
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250 Interestingly, while the S-LV luciferase signal achieved upon treatment with 
251 rAAV8.NC0321 tended to be lower than that with negative control T1-3B mAb, 
252 indicating a modest positive treatment effect (~ 0.18 log or 31.2% protection), this was 
253 not statistically significant (p=0.2605). Together, these data suggest that the intranasal 
254 delivery of rSIV.F/HN or rAAV9.NC0321 can confer robust protection against a 
255 saturating infectious dose of a SARS-CoV-2 mimic.
256
257 Importantly, we also confirmed that NC0321 from mouse serum retained biological 
258 function in an in vitro neutralisation assay. As expected, sera from mice receiving the 
259 control rAAV8.T1-3B vector showed no neutralizing activity against an S-LV 
260 expressing eGFP, whereas sera from mice receiving the rAAV8.NC0321 vector 
261 demonstrated potent neutralizing activity (Supplementary Fig 1E); this confirms that 
262 rAAV8.NC0321 treatment resulted in the production of biologically active NC0321. 
263 Moreover, binding assays showed that rAAV8.NC0321 sera were able to bind to six 
264 different RBD proteins including some with mutations that appear to confer enhanced 
265 infection or the potential to escape pre-existing immunity 17. These include Wuhan 




270 In this study, we firstly generated S-LV, a third-generation lentiviral vector 
271 pseudotyped with the SARS-CoV-2 Spike protein. Like native SARS-CoV-2, cellular 
272 infection by S-LV requires hACE2. Subsequently we created an in vivo model of 
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273 SARS-CoV-2 infection that can be readily produced using standard laboratory animals, 
274 by expressing hACE2 in trans from rAAV hACE2 vectors. Importantly, there appeared 
275 to be a positive correlation between the dose of rAAV.hACE2 and the S-LV infection 
276 in this humanised mouse model. Our result suggests that rAAV.hACE2 priming should 
277 permit authentic SARS-CoV-2 infection. Thus our in-house humanised mouse model,  
278 generated by rAAV-mediated hACE2 overexpression, should be suitable for studying 
279 authentic SARS-CoV-2 infections and evaluating other prophylactic or therapeutics 
280 options. A similar approach to mouse model generation was reported in the studies 
281 performed by Israelow 18, Han 19 and Sun 20 where both adenoviral vector (rAd) and 
282 rAAV vector approaches were utilised. Importantly, rAAV transduction is associated 
283 with lower vector-mediated inflammation and immunogenicity than rAd treatment 21, a 
284 feature that may allow generation of a more informative mouse model. Importantly, 
285 while murine models of SARS-CoV-2 infection tend not to demonstrate the full range 
286 of pathology observed following human infection 22, they can provide simple, rapid, 
287 pharmacodynamic assays to evaluate interventions to modulate viral titres. One major 
288 limitation of the hACE2 expressing murine model we adopted is that the biodistribution 
289 of hACE2 mediated by intranasal rAAV9 transduction may not be identical to that of 
290 natural hACE2 in human lungs – where expression is predominantly noted on the apical 
291 surface of alveolar type II cells 23. Crucially, studies described here could be completed 
292 in standard animal laboratories without the need for the very high levels of biological 
293 containment required for utilising SARS-CoV-2, and without the cost and animal 
294 wastage associated with the maintenance, breeding and supply of hACE2 transgenic 
295 animals. Therefore, this unique rAAV-hACE2/S-LV model could provide a rapid and 
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296 efficient method to researchers interested in studying COVID-19 and other respiratory 
297 pathogens, regardless of the limitations of biosafety level and the availability of 
298 commercial humanised animal models.  
299
300 Subsequently, using our humanised (hACE2-expressing) murine model, we evaluated 
301 the performance of alternative VIP strategies. We chose rSIV.F/HN, rAAV9, and 
302 rAAV8 vectors to establish NC0321 expression in vivo as we, and others, have had 
303 previous positive experiences expressing a range of IgG molecules with these vectors 9 
304 24-26. We established a significant degree of protection against infection of 470 ng p24 
305 of our SARS-CoV-2 mimic at, or near, the primary site of inoculation of respiratory 
306 pathogens. Both rAAV9 and rSIV.F/HN mediated NC0321 expression via I.N. delivery 
307 can result in significant prophylactic efficacy against a saturating infectious inoculum 
308 of S-LV. It would be reasonable to assume that this treatment effect would be even 
309 more marked against a more typical environmentally acquired (sub-saturating) SARS-
310 CoV-2 infection. One caveat to these finding was the magnitude of the prophylactic 
311 efficacy observed. While both rAAV9 and rSIV.F/HN mediated NC0321 expression 
312 resulted in a significant reduction in S-LV infection, this inhibition was not total, and 
313 residual S-LV infection was still observed. Any consequences of this limitation remain 
314 to be elucidated in follow-on studies. Crucially, both rAAV9 and rSIV.F/HN vectors 
315 have been shown to provide life-long sustained IgG expression 9, and the unique 
316 rSIV.F/HN platform can also be effectively repeatedly administered 27 28 should 
317 therapeutic antibody levels need to be boosted to improve efficacy or augmented with 
318 alternate mAbs to inhibit immune escape.
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319
320 Interestingly, despite antibody expression from rAAV8 vectors being considered for 
321 treatment of a number of pathogens of importance 29 30, and rAAV8 vector being 
322 thought to mediate transgene expression more ubiquitously than other rAAV serotypes 
323 31, we found relatively poor performance with rAAV8. A number of potential mitigating 
324 circumstances/explanations for these findings with rAAV8 can be postulated, such as 
325 unfavourable expression kinetics (though largely discounted by the speed of NC0321 
326 appearance in the serum), or unfavourable biodistribution and antibody clearance 
327 (largely discounted by the accumulation of NC0321 in the ELF). 
328
329 Despite the complexity of our experimental setting, mice did not show symptoms of 
330 stress (e.g. weight loss) during the experiments (Supplementary 1F); and thus all the 
331 studies reported here were performed whilst imposing, at worst, only mild perturbations 
332 of the animals physiology – a significant refinement over traditional approaches to 
333 respiratory pathogen challenge/protection studies where humane endpoints are often 
334 utilised to minimise animal suffering. Importantly, studies assessing the degree of 
335 protection offered against more realistic (sub-saturating) infective S-LV doses and 
336 challenge with authentic SARS-CoV-2 will be incorporated in future work. Such 
337 studies may include evaluation of survival and immunological consequences.
338
339 Importantly, we showed that NC0321 can bind to different SARS-CoV-2 variants (Fig 
340 5D) including: the RBD mutation N501Y present in the Alpha (B.1.1.7) lineage SARS-
341 CoV-2 strain widely circulating in the UK at the beginning of 2021 32; the RBD with 
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342 mutation Y453F is found in the mink-associated CoV-2 variant in the Netherlands. The 
343 binding and neutralizing activity of NC0321 with other strains is currently being 
344 investigated, including the Beta lineage (B.1.351) first identified in South Africa (with 
345 key mutations N501Y+E484K+K417N) and Gamma lineage (P.1) first identified in the 
346 Brazilian population (with key mutations K417T+E484K+N501Y). We are also 
347 investigating whether the binding activity of NC0321 is compromised with the crucial 
348 E484K mutation. If not, NC0321 may be rapidly adapted in a COVIP setting for these 
349 newly emerging and more infectious SARS-CoV-2 clades. Notably, our approach is not 
350 limited to NC0321 antibody or to the use of a single mAb reagent. Indeed, we note that 
351 serum levels of NC0321 achieved following in vivo vector delivery were lower than 
352 can be achieved by optimisation of the IgG backbone sequences 8. Thus, enhanced 
353 derivatives of NC0321 or emerging mAbs with higher potency and more broadly 
354 neutralizing activity 33 34 could be readily assembled in rAAV9 or rSIV.F/HN vectors. 
355 Importantly, a cocktail strategy with multiple mAbs containing non-overlapping/non-
356 competing antigen binding to Spike and other SARS-CoV-2 targets could be used to 
357 enhance the protection offered and prevent rapid mutational escape 35. For example, the 
358 Regeneron’s antibody cocktail Ronapreve (casirivimab and imdevimab) authorized by 
359 US Food and Drug Administration (FDA) 36. Similarly, soluble receptor decoys 
360 engineered to efficiently neutralize SARS-CoV-2 could be incorporated into the vector 
361 cocktail to boost our SARS-CoV-2 inhibitory strategy 37-39. 
362
363 In conclusion, by using a versatile, humanised mouse model and SARS-COV-2 mimic, 
364 we evaluated a VIP strategy against COVID-19. An intranasal delivery route was 
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365 simple to implement and the long duration of IgG expression observed benefited from 
366 the very slow turnover rate of lung cells. In murine studies, the lung tissue is easily 
367 accessible for localised vector administration via instillation. When translated to 
368 humans, this prophylactic approach could be delivered via nasal spray to provide 
369 protection against respiratory diseases in all recipients; these include but are not limited 
370 to vulnerable individuals who are unable to mount an effective immunological response 
371 to either SARS-CoV-2 infection or vaccination. 
372
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545 Figure 1. S-LV infection requires hACE2, which can be supplied to mouse lungs by 
546 rAAV in vivo gene transfer 
547 A WT parental HEK293T/17 cells, and HEK293T/17 cells expressing hTMPRSS2, 
548 hACE2, or both hACE2 & hTMPRSS2 as indicated, were infected with an S-LV 
549 expressing eGFP. The percentage of S-LV transduced cells was evaluated by flow 
550 cytometry. The dotted line represents the limit of quantification. One-way ANOVA, 
551 with Dunnett’s multiple comparisons test (ns and ***** represent p>0.05 and p<0.0001 
552 respectively).
553 B Lung immunohistochemistry for eGFP was assessed in BALB/c (9-week old) mice 
554 14 days after intranasal delivery of 1xD-PBS (control), 1E11 GC of rAAV9 or 7E10 
555 GC rAAV6.2 vectors expressing eGFP (n=3/group). Scale bar = 500 𝜇𝑚.
556 C Lung sections were subjected to RNAscope in situ hybridization analysis 14 days 
557 after intranasal delivery of 1xD-PBS (control), 1E11 GC of rAAV9 or 7E10 GC 
558 rAAV6.2 vectors expressing hACE2 (n=3/group); hACE2 vector-specific WPRE probe 
559 (red), alveolar type II cell specific Sftpb probe (green), DAPI stained nuclei (blue). AW, 
560 airway; P, parenchyma. Scale bar = 125 𝜇𝑚.
561
562 Figure 2. In vivo delivery of hACE2 allows the SARS-CoV-2 mimic S-LV to infect the 
563 lungs of standard laboratory mice  
564 A Experimental design for in vivo investigation of hACE2/hTMPRSS2 delivery via 
565 rAAV vectors to support S-LV infection. BALB/c mice (n=4-8/group) were transduced 
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566 intranasally with the indicated rAAV vector(s) or vehicle (1xD-PBS). At 14 days post 
567 rAAV delivery, as indicated, lungs were infected with 890 ng p24 of an S-LV 
568 expressing firefly luciferase. S-LV dependent in vivo luciferase bioluminescence was 
569 monitored for each animal 1, 2, 4, 7, 14, 21 and 38 days post S-LV infection. 
570 B Representative in vivo bioluminescence images of mice pre-treated 14 days 
571 previously with the indicated doses of rAAV.hACE2 and hTMPRSS2 vectors and, as 
572 indicated, subsequently challenged with 890 ng p24 of S-LV at day 0. Repeated 
573 bioluminescence imaging of S-LV dependent luciferase expression was performed at 
574 the indicated time points. Bioluminescence values (photons/sec/cm2/sr) are presented 
575 as a pseudocolour scale as indicated.  
576
577 C Time-course of bioluminescence for the indicated treatment groups after infection 
578 with 890 ng p24 of S-LV. Symbols represent group mean±SD, n=4-8 per group. The 
579 dotted line indicates the mean naïve background signal. 
580 D Area Under Curve (AUC) of bioluminescence values (photons/sec/cm2/sr x days) for 
581 each animal in B & C was computed, symbols represent individual animals and group 
582 mean±SD (ANOVA, Dunnett’s multiple comparison against the unlabelled treatment 
583 group (1E11 GC rAAV9.hACE2); ns, * and **** represent p>0.05, <0.05 and <0.0001 
584 respectively).
585
586 Figure 3. S-LV mouse lung infection is limited by hACE2 availability
587 A Experimental design for in vivo investigation of S-LV dose-response. BALB/c mice 
588 (n=3/group) were dosed I.N. with 1E11 GC rAAV9.hACE2 to establish hACE2 
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589 expression. Fourteen days later, lungs were infected with 0-940 ng p24 of an S-LV 
590 expressing firefly luciferase. S-LV dependent in vivo luciferase bioluminescence was 
591 monitored for each animal 1, 2, 4 and 7 days post S-LV infection. 
592 B Representative in vivo bioluminescence images of mice, treated as described in A. 
593 Repeated bioluminescence imaging to monitor S-LV dependent luciferase expression 
594 was performed at the indicated time points. Bioluminescence values 
595 (photons/sec/cm2/sr) are presented as a pseudocolour scale as indicated.
596 C Time-course of bioluminescence after S-LV infection for the indicated treatment 
597 groups as described in A. Symbols represent group mean±SD, n=4-8 per group. The 
598 dotted line indicates the mean naïve background signal.
599 D Area Under Curve (AUC) of bioluminescence (photons/sec/cm2/sr x days) for each 
600 animal in C was computed, symbols represent group mean±SD (ANOVA, Dunnett’s 
601 multiple comparison against the unlabelled treatment group (470ng p24); ns, **, *** 
602 and **** represent p>0.05, p<0.05, <0.001 and <0.0001 respectively).
603
604 Figure 4. NC0321 mAb expression by rAAV and rSIV.F/HN vectors
605 A Schematic of a codon-optimised, single open-reading frame, human IgG mAb cDNA. 
606 Regions encoded include IgG heavy and kappa light chain variable and constant regions, 
607 with each proceeded by a human growth hormone signal sequence (hGH SS) and joined 
608 by a Furin/2A (F2A) protein cleavage site.   
609 B The SARS-CoV-2 RBD protein binding activity of the anti-SARS-CoV-2 mAbs 
610 NC0321 and CR3022 single open reading frame protein expressed from an rSIV.F/HN 
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611 vector) was examined by ELISA. Binding activity of OD at 450nm is proportional to 
612 the amount of antibody bound to the SARS-CoV-2 RBD protein. 
613 C The neutralising activity of anti-SARS-CoV-2 mAb NC0321 (single open reading 
614 frame protein expressed from an rSIV.F/HN vector) to block S-LV infection 
615 (multiplicity of infection 1) of an hACE2-293T cell line was examined. In B&C a single 
616 open reading frame anti-influenza mAb T1-3B acted as an isotype negative control; and 
617 CR3022 an anti-SARS-CoV neutralizing mAb, that can bind but not neutralize SARS-
618 CoV-2 was used as a comparator 40.
619 D Serum human IgG levels in mice were determined at day 7, 14 and 28 after 
620 transduction with the indicated doses of NC0321 expressing vector using ELISA 
621 (ANOVA, Dunnett’s multiple comparison against the unlabelled treatment group; *** 
622 and **** represent <0.001 and <0.0001 respectively). The levels of human IgG 
623 observed in naïve animals is indicated by the dotted line.
624 E BALF of mice from D was collected at day 28 post transduction with NC0321 
625 expressing vector, and human IgG levels measured using ELISA; IgG levels in 
626 Epithelial Lining Fluid (ELF) were computed by comparison of urea levels in BALF 
627 and serum (Kruskal Wallis, Dunn’s multiple comparison against the unlabelled 
628 treatment group; ns, **,*** and **** represent p>0.05, <0.01, <0.001, and <0.0001 
629 respectively). Each dot represents an individual mouse and data are presented as 
630 endpoint titres (Mean±SD). 
631
632 Figure 5. Vector-mediated expression of NCO321 antibody protects against S-LV 
633 infection
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634 A Experimental design to test efficacy of the COVIP strategy in vivo. Groups of mice 
635 were dosed as indicated (groups 1 to 7) under a single anaesthesia to establish hACE2 
636 and NC0321 expression. Twenty-one days later, animals were infected with an S-LV 
637 expressing firefly luciferase (Day 0) and, subsequently, S-LV dependent in vivo 
638 luciferase bioluminescence monitored for each animal on days 1, 2, 4 and 7. Serum and 
639 BALF samples were taken at indicated times for determination of NC0321 IgG levels. 
640 B Vectored delivery and expression of NC0321 to mouse lungs significantly inhibits S-
641 LV infection. Groups 1-7 of BALB/c mice (n=10/group) were treated as indicated and 
642 after 21 days infected with 470 ng p24 of an S-LV expressing firefly luciferase (Day 
643 0). Representative images of in vivo bioluminescence are shown 7 days post S-LV 
644 infection for each of the 6 treatment groups. Bioluminescence values 
645 (photons/sec/cm2/sr) are presented as a pseudocolour scale as indicated.
646 C Area Under Curve (AUC) of bioluminescence (photons/sec/cm2/sr x days) for each 
647 animal in B was computed. To aid visualisation, bioluminescence values were 
648 normalised such that T1-3B isotype control values were 100%. Control values were 
649 obtained from animals that were infected with S-LV but had not received rAAV9-
650 hACE2. Group mean±SD is indicated (ANOVA, Dunnett’s multiple comparison 
651 against the unlabelled treatment group; ns, **, *** and **** represent p>0.05, <0.01, 
652 <0.001 and <0.0001 respectively). 
653 D Serum from mice 28 days post receiving rAAV8.NC0321 was collected, and limiting 
654 dilutions were made to measure the binding activity against SARS-CoV-2 Spike or 
655 RBD proteins of newly emerging SARS-CoV-2 variants as indicated. Negative control 
656 is binding activity observed with cell culture medium only.  




































































Viral vector genome plasmids were engineered to include for rAAV8 a muscle-
optimised CASI promoter 1, for rAAV9 the lung optimised hCEFI promoter 2, or for 
rSIV the hCEF derivative, lacking a chimeric intron 3; all incorporated the Woodchuck 
Hepatitis Virus Post-transcriptional Regulatory Element (WPRE) to enhance 
expression 4, and a mirT-142-3p to improve immunologic tolerance 5. Vectors used 
included eGFP, firefly luciferase or chimeric human IgG1 cDNAs (NC0321 anti-
SARS-CoV-2 or T1-3B anti-influenza); IgG heavy and light chains were co-expressed 
in a single open reading frame (ORF) configuration 6. For rAAV6.2 or rAAV9 hACE2 
expression, a similar vector genome configuration with the CMV transgene promoter 
was used. The S-LV genome was a third-generation HIV vector including a CMV 
transgene promoter and an eGFP or firefly luciferase cDNA. 
 
The production of rAAV, rSIV.F/HN and S-LV vectors was performed by co-
transfection of human embryonic kidney (HEK) 293T cells with genome and packaging 
plasmids using (rAAV) Polyethylenimine (PEI, PolySciences) or (rSIV.F/HN and S-
LV) PEIpro® (Polyplus). All AAV vecto s included AAV2-based vector genomes. 
Alternate AAV serotypes were produced by use of AAV2 Rep and appropriate serotype 
Cap sequences. All rSIV vectors were pseudotyped with the F and HN proteins of 
Sendai virus as described previously 3. The S-LV (rHIV.Spike.G614+∆19aa.CMV) 
vector was pseudotyped with the SARS-CoV-2 Spike protein Wuhan sequence 
(GenBank accession: 43740568) modified by inclusion of a D614G mutation and 
removal of the 19 C-terminal amino acids. Vectors were purified by (rAAV) 
discontinuous Iodixanol gradient ultracentrifugation 7 or (rSIV.F/HN, S-LV) anion 
exchange chromatography and tangential flow filtration.  
 
Physical titre (genome copies/mL: GC/mL) of rAAV vectors was determined by 
quantitative polymerase chain reaction (qPCR) analysis with primers and a probe 
against WPRE 8. Functional titre of rSIV.F/HN vectors (transducing units/mL: TU/mL) 
was determined using the same primer/probes on DNA extracted following 
transduction of HEK293F cells with dilutions of vector preparations 9. Physical titre (ng 
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All procedures involving laboratory mice were carried out in accordance with UK 
Home Office approved project and personal licenses under the terms of the Animals 
(Scientific Procedures) Act 1986 (ASPA 1986). Animals were arbitrarily assigned to 
study groups using an open-label randomised block approach. Overall, 134 animals 
were used (Fig 1: n=15, Fig 2: n=34, Fig 3: n=15, Fig 4/5: n =70). 
 
Vector administration 
Female BALB/c mice (5-8 week) were purchased from Envigo RMS UK. For all dosing 
procedures, mice were lightly anaesthetised by isoflurane. Where lung expression of 
hTMPRSS2 and/or hACE2 was required, cocktails of rAAV vectors were delivered by 
nasal instillation (I.N.) of a 100µL volume onto the nares via a single and continuous 
droplet 10. Where mAb or control transgene expression was required, the relevant 
rAAV9 or rSIV.F/HN vector was included in the same cocktail. For intramuscular 
injection (I.M.) (AAV8), a 50 µL volume was injected via 22-gauge needle into the 
gastrocnemius muscle 9. After the indicated period, specified animals were challenged 
with S-LV, which was also delivered via nasal instillation as described.  
 
Immunohistochemistry and In Situ Hybridization  
Left lung sections of BALB/c mice were isolated and fixed ith 4% paraformaldehyde, 
embedded in sucrose 30% (w/v) at RT overnight, followed by injection of Optimal 
Cutting Temperature medium and 30% (w/v) sucrose mixture. The embedded left lung 
was cryo-sectioned at 7 μm thickness. For immunohistochemistry (IHC) analysis, 
sections from each sample was stained after antigen retrieval. Slides were washed, 
permeabilised, blocked, followed by the incubation in 20 μg/ml of primary antibody 
anti-eGFP antibody (ab6556, 1:1000, Abcam) overnight and subsequently with 
secondary antibody Goat Anti-Rabbit IgG H&L (Alexa Fluor 488, ab150077, at 1:500, 
Abcam). Sections were mounted under coverslips with DAPI pro-long antifade 
(P36935, Invitrogen™) before imaging using an EVOS FL2 fluorescence microscope 
with an 20X long working distance objective. For In Situ Hybridization, slides were 
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probed targeting the WPRE sequence (WPRE-O1, ACD, #450261) found in all AAV 
expression cassettes in this study, and/or the ATII cell marker Surfactant protein B 
(Sftpb-noX-human, ACD, #539421-C2) according to the RNAscope® manufacturer’s 
instructions (323100-USM, ACD). Opal dyes 520 and 570 (#NEL741E001KT and 
#NEL744E001KT, 1:1500, Perkin Elmer) were used to visualise the Sftpb and WPRE 
signal, respectively. 
 
In Vivo Luciferase Imaging  
In vivo lung luciferase activity was determined following S-LV administration using 
IVIS spectrum imaging system (IVIS Lumina LT, Series III, PerkinElmer). This highly 
sensitive and linear method to determine lung transgene expression levels 11 can be 
achieved utilising recovery anaesthesia - allowing repeated measure in the same animal, 
allowing a substantial reduction in animal numbers over conventional luciferase 
activity measures that require lung tissue that can only be provided with a terminal 
procedure. Briefly, at the chosen time-points, in vivo lung luciferase activity was 
determined 10 minutes after mice were administered 100 μl 15 mg/ml D-luciferin 
(Xenogen Corporation Alameda) via the I.N method described for vector 
administration. Average bioluminescence (photons/sec/cm2/sr) values are presented 
using a pseudo colour range to represent light intensity. Bioluminescence in each 
murine lung was measured within a standardised tissue area.  
 
IgG expression profiling and binding activity  
At indicated time points post vector delivery, serum and Broncho alveolar lavage fluid 
(BALF) was obtained 9. Human IgG expression in serum and BALF was measured by 
ELISA (anti-Human IgG Fc domain, Bethyl Laboratories) according to the 
manufacturer’s instructions. Urea levels were measured in serum and BALF (ab83362, 
Abcam). The concentrations of IgG levels in epithelial lining fluid (ELF) were 
determined by correcting for BALF sample dilution via normalizing found urea levels 
in serum and BALF 12. 
 
Statistical analysis  
Treatment group sizes were selected to achieve >0.8 power using G*Power 3.1.9.6 
software 13. Post-hoc statistical analysis was performed using Prism 8.4.3 (GraphPad 
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Software). Where possible, comparisons of multiple treatment groups were performed 
using one-way ANOVA followed by Dunnett’s multiple comparisons test to a chosen 
comparator group or Tukey’s comparison of all groups as appropriate; if necessary, data 
were log-normalised to assure adherence to the assumptions of ANOVA. Where the 
assumptions of one-way ANOVA were violated, the non-parametric Kruskal-Wallis 
test followed by Dunn’s multiple comparisons test to a chosen comparator group was 
used. Where indicated, Area Under Curve (AUC) of time-course studies were computed 
from individual data, multiple comparisons of AUC between treatment groups were 
performed as described above. Errors were reported as the standard deviation of the 
mean (SD). In all cases, p value < 0.05 was considered statistically significant. In 
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Supplementary Figure 1 
A SDS-PAGE analysis reducing (left) and non-reducing (right) of produced 
monoclonal antibody. In reduced form, two bands were shown in 50 and 25 kDa and in 
non-reducing SDS-PAGE condition, only one band was seen in about 150 kDa 
indicating full length of IgG.  
B Delivery of rAAV9 NC0321 and rSIV.F/HN.NC0321 to mouse lungs significantly 
inhibits S-LV infection. BALB/c mice (n=10/group) were treated with the indicated 
doses of rAAV9.hACE2, and rSIV.F/HN, rAAV9 or rAAV8 expressing either NC0321 
or the T1-3B isotype control by the I.N. or I.M. route as indicated. 21 days later, mice 
were infected with 470 ng p24 of an S-LV expressing firefly luciferase. Representative 
in vivo bioluminescence images of mouse lungs 7 days post S-LV infection are shown 
for each treatment group. Bioluminescence values (photons/sec/cm2/sr) are presented 
as a pseudocolor scale as indicated Of note: one mouse in rAAV9.T1-3B group had 
very low bioluminescent signal, this was likely caused by a failure to deliver S-LV. 
This animal’s data was included in the group analysis.  
C Time-course of bioluminescence imaging data for the indicated treatment groups 
after infection with 470 ng p24. Symbols represent group mean±SD. The dotted line 
indicates the mean naïve background signal.  
D Area Under Curve (AUC) of bioluminescence (photons/sec/cm2/sr x days) values for 
each animal receiving T1-3B was computed, symbols represent individual animals and 
group mean±SD (ANOVA, Dunnett’s multiple comparison against the unlabelled 
treatment group; ns, and **** represent p>0.05 and <0.0001 respectively). The dotted 
line indicates the mean signal from naïve mice.   
E Sera from animals receiving rAAV8.NC0321 inhibit S-LV.eGFP infection of 
hACE2+hTMPRSS2-expressing 293T cells (representative of n=2 independent 
infections). 
F Weights of mice treated as described in A (n=10/group). Box and whisker plots 
represent the indicated treatment groups (inter-quartile range is shown as coloured 
vertical bars, group median is indicated with the horizontal line, whisker represent the 
5-95% range).  
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SP057 - LV-S vGM263 transduction comparison - eGFP%
✱✱✱, p=0.0001
✱✱✱✱, p<0.0001
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Binding activity with 0.1 µg SARS-CoV-2 RBD 
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